Perspective Therapeutics, Inc. business relationships
Companies named in Perspective Therapeutics, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name Perspective Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 5 / 100 Top 3% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in Perspective Therapeutics, Inc.’s annual report 1
“In March 2024, we entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety and tolerability of [ 212 Pb]VMT01 in combination with Bristol Myers Squibb's checkpoint inhibitor nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging sca...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.